Actively Recruiting
Clinical Prognostic Score to Predict Relapse in VL
Led by Institute of Tropical Medicine, Belgium · Updated on 2024-03-05
741
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
Sponsors
I
Institute of Tropical Medicine, Belgium
Lead Sponsor
U
University of Gondar
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia. Therefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.
CONDITIONS
Official Title
Clinical Prognostic Score to Predict Relapse in VL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically or parasitologically confirmed visceral leishmaniasis (VL)
You will not qualify if you...
- Age under 12 years
- VL patients already on treatment for 3 days or more
- Severe critical condition or other medical reasons making study participation inadvisable
- Unlikely to adhere to follow-up visits or unreachable by phone
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Gondar
Gonder, Ethiopia
Actively Recruiting
Research Team
S
Saskia van Henten, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here